Alternative to Chemotherapy

AB001: Radical Innovation in Immunotherapy

B-cell Centric and T-cell Augmenting Novel Immuno-Oncology

AB001 Novel Immunotherapy
Beyond PD-1/PD-LI Inhibitors

AB001 Unique Features
  • Negligible toxicity and no observable side effects
  • Targets only cancer cells. No harm to normal cells
  • Targets cancer stem cells and degrades them
  • Inhibits multiple checkpoints including PD-L1
  • Triggers apoptosis via MEK/JAK/STAT via the PI3K pathway
  • Inhibits beta-catenin transcriptional activity to overcome the resistance and relapse
  • No relapse has been observed in vivo

What is the difference between AB001 and other PD-1/PD-L1 inhibitors?

PD-1 inhibitors result in creating a number of serious side effects. AB001 is a B cell-centric and T cell augmentation small molecule which works on both B cells and T cells. Other check point inhibitors deal primarily with T cell empowerment. AB001 induces B cells for the production of tumor clearing antibodies, predominantly IgG1.

“B cells are at the centre of the adaptive humoral immune system … directed against invasive pathogens.” — British Society for Immunology

AB001 PD1/PDL1 Inhibition

AB001 is a novel small molecule inhibitor that actively targets multiple pathways in cancer cells. It targets and binds specifically with PD-L1 on tumor cells and inhibits the downstream signaling of the PD-1 pathway that can restore the normal function of T cells.

Blockage of PD-1/PD-L1 interaction results in the reversal of the exhausted T-cell phenotype and normalization of antitumor response, providing the rationale of targeted therapy. It also stimulates B cells to secrete tumor-eliminating antibodies and inhibits the suppression of regulatory cells by Inhibiting IL-10 and TGF beta.

Pathways Inhibited by AB001

Being a small molecule it easily transverses through the plasma membrane and targets multicellular pathways such as WNT/β Catenin, PI3K, MAPK pathway, which are mainly involved in cellular proliferation survival and resistance.

None of the currently available chemo drugs target cancer stem cells due to their slow-growing ability, fast differentiation and expansion, which are responsible for relapse and recurrence.

AB001 is the first small molecule that eliminates cancer stem cells from the root via the beta-catenin pathway and degrades them. Furthermore, toxicity studies prove the safety of the molecule making it a promising alternative candidate for chemotherapy.

AB001 Overcoming Resistance of Immune Checkpoint Inhibitors 

AB001 B Cell-centric & T Cell Augmentation: Novel Immuno-Oncology

  • AB001 induces B cells for the production of tumor clearing antibodies, predominantly IgG1:
    • mediating antibody dependent cell-mediated cytotoxicity (ADCC)
    • mediating antibody dependent cell-mediated phagocytosis (ADCP)
    • facilitating complement activation
  • Activation of CD4 helper cells and CD8 cytotoxic T cells
  • Inhibition of CD4 regulatory T cells and B regulatory cells
  • Inhibition of IL-10, TGF beta which inhibit effector function of T cells

“B cells can also promote differentiation of Th1, Cytotoxic T-cell and can aid in better T cell mediated immune response. The release of Granzyme B can directly kill cancer cells and support the tumor suppressive actions of B-cells in tumor microenvironment. Release of IFNα can stimulate TLR agonist to kill tumor cells through the TRAIL signaling activity” – Sarvaria, Cellular & Molecular Immunology, Aug 2017